Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...

US President Donald Trump announced plans to impose tariffs on imported computer chips pharmaceuticals and steel aiming to drive more manufacturing within the United States ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer.

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.